Dapagliflozin Approval UK (Forxiga) - MHRA Status
Forxiga is MHRA-approved in the UK for type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease. See approval details and dates.
Dapagliflozin
35 source-based articles maintained by the HealthRX.com Editorial Team.
35articles
5topic areas covered
May 25, 2026latest review
Dapagliflozin library
Showing 35 of 35 clinical reviews.
Dapagliflozin First Approved: FDA Timeline Since 2014
Dapagliflozin (Farxiga) first won FDA approval on January 8, 2014 for type 2 diabetes, then expanded to heart failure in 2020 and chronic kidney disease in 2021.
Dapagliflozin in Pregnancy: Risks and Safer Alternatives
Dapagliflozin is contraindicated in the 2nd and 3rd trimesters due to fetal renal toxicity; insulin is the preferred option for diabetes in pregnancy.
Dapagliflozin Metabolism: UGT1A9 and CYP Role in Farxiga Label
Dapagliflozin is metabolized mainly by UGT1A9, not CYP enzymes; variants can shift drug exposure 15-55%, though no FDA dosing change is required.
Dapagliflozin Patent Expiry Date and Generic Timeline
Farxiga's core patent expires October 2026, with pediatric exclusivity possibly pushing generics to April 2027. Four ANDA filers have already challenged it.
Dapagliflozin Prescribing Info: Dosing for Ages 50-64
Dapagliflozin dosing for adults 50-64: 10 mg once daily for T2D, HFrEF, HFpEF and CKD; no age-based adjustment, but check eGFR before and during treatment.
Dapagliflozin Renal Dose: eGFR Thresholds Explained
Dapagliflozin stays at 10 mg daily regardless of kidney function. Starts at eGFR ≥25; continue until dialysis or transplant. DAPA-CKD data included.
Does Farxiga Cause Bladder Cancer? FDA Findings
Early bladder cancer concerns with Farxiga were resolved after review; FDA signals now focus on DKA, serious UTIs and Fournier gangrene.
Does Humana Cover Farxiga (Dapagliflozin)? Coverage, Prior Auth, and Appeals
A detailed guide to Humana's formulary status for Farxiga (dapagliflozin), prior-authorization criteria, step-therapy requirements, appeal strategies, and cost-reduction options for 2024 to 2025.
Does TRICARE Cover Farxiga (Dapagliflozin)? Coverage, Prior Auth, and Appeals Explained
A complete guide to TRICARE coverage of Farxiga (dapagliflozin) for type 2 diabetes, heart failure, and CKD, including formulary tier, prior authorization criteria, step therapy requirements, and how to appeal a denial.
Does UnitedHealthcare Cover Farxiga (Dapagliflozin)?
A complete guide to UnitedHealthcare coverage for Farxiga (dapagliflozin), including formulary tier, prior authorization criteria, step therapy requirements, appeals, and cost-saving options for type 2 diabetes, heart failure, and CKD.
Farxiga (Dapagliflozin) Complete Drug-Drug Interaction Profile
Dapagliflozin is cleared mainly by UGT1A9 glucuronidation to an inactive 3-O-glucuronide. CYP450 does little, so CYP-based drug interactions stay limited.
Farxiga (Dapagliflozin) Food & Supplement Interactions
Evidence-based guide to dapagliflozin food and supplement interactions, including alcohol, high-sodium diets, diuretic herbs, and common supplements that affect SGLT2 inhibitor safety and efficacy.
Farxiga (Dapagliflozin) Manufacturing, Supply Chain & Shortage History
A review of how Farxiga (dapagliflozin) is manufactured, AstraZeneca's supply chain structure, FDA shortage-listing status, and the pharmacology behind this SGLT2 inhibitor, with notes on where claims need primary-source verification.
Farxiga (Dapagliflozin) Missed-Dose Protocol: What to Do and When to Skip
Evidence-based guide to handling a missed dose of Farxiga (dapagliflozin). Covers timing rules, pharmacokinetics, clinical context for type 2 diabetes, heart failure, and CKD indications, plus what requires a call to your prescriber.
Farxiga (Dapagliflozin) Off-Label Uses with Evidence Levels
A clinician-grade review of dapagliflozin (Farxiga) off-label uses, ranked by evidence level. Covers obesity, MASLD, type 1 diabetes, polycystic kidney disease, gout, and more, with trial data and guideline citations.
Farxiga (Dapagliflozin) Safety in Older Adults 65 and Over
Evidence-based guide to dapagliflozin (Farxiga) safety in geriatric patients 65+, covering renal considerations, hypotension risk, fracture data, drug interactions, and deprescribing strategies.
Farxiga (Dapagliflozin): What to Expect Week by Week in Your First Month
A week-by-week guide to what Farxiga (dapagliflozin) does in your first 30 days, covering blood sugar, weight, blood pressure, urinary side effects, and when to call your doctor.
Farxiga Appetite & Cravings Changes: What the Clinical Evidence Shows
Does Farxiga (dapagliflozin) reduce appetite or change food cravings? A PharmD/MD-level review of the mechanisms, clinical trial data, and what patients can realistically expect.
Farxiga Cardiovascular Impact Long-Term: What the Evidence Actually Shows
A deep dive into dapagliflozin's long-term cardiovascular effects, covering DAPA-HF, DECLARE-TIMI 58, DAPA-CKD, and current prescribing guidance for HFrEF, HFpEF, and CKD populations.
Farxiga Dosing: 5mg to 10mg Guide for Young Adults
Farxiga dosing starts at 5 mg once daily, increasing to 10 mg max based on tolerability. Same protocol applies ages 18-29, no age adjustment needed.
Farxiga for Prediabetes: What the Evidence Actually Shows
Dapagliflozin (Farxiga) is not FDA-approved for prediabetes, but emerging trial data suggest it may reduce diabetes progression in high-risk patients. Learn what the evidence shows, how clinicians use it off-label, and what alternatives exist.
Farxiga Generic: Availability, Cost & Alternatives (2026)
No generic dapagliflozin yet in the U.S.; patent expires 2026. Farxiga runs ~$580/month vs. Jardiance ~$590 and Invokana ~$570. Compare costs and efficacy.
Farxiga Hair and Skin Changes: What Dapagliflozin Does to Your Body
A guide to dapagliflozin (Farxiga) hair loss and skin changes, including genital mycotic infections, rash incidence from clinical trials, and what to do if symptoms appear.
Farxiga Hold Before Surgery: Stop 3-4 Days Prior
Stop dapagliflozin 3 to 4 days before elective surgery to avoid euglycemic DKA risk. Resume once eating normally and kidney function is stable.
Farxiga Liver Function Impact: What Dapagliflozin Does to ALT, AST, and Hepatic Fat
A clinician-level review of how dapagliflozin (Farxiga) affects liver enzymes, hepatic steatosis, and fibrosis markers, with primary-literature citations and dosing guidance for patients with hepatic impairment.
Farxiga Mental Health and Mood Impact: What the Evidence Actually Shows
A clinical deep-dive into how dapagliflozin (Farxiga) affects mental health, mood, depression risk, and quality of life. Covers DAPA-HF, DAPA-CKD, and emerging mechanistic data with physician-level citations.
Farxiga Monitoring Schedule: Labs & Exams You Need on Dapagliflozin
A physician-level guide to the lab tests, imaging, and clinical exams required while taking dapagliflozin (Farxiga), with exact timing intervals and evidence-based rationale.
Farxiga Muscle Preservation Strategies: What the Evidence Says About Dapagliflozin and Skeletal Muscle
Evidence-based guide to muscle preservation strategies for patients on Farxiga (dapagliflozin), covering the mechanistic rationale, clinical trial data, and actionable co-interventions to protect lean mass.
Farxiga Pharmacokinetics (ADME): How Dapagliflozin Is Absorbed, Distributed, Metabolized, and Eliminated
A clinician-grade breakdown of dapagliflozin (Farxiga) pharmacokinetics covering absorption, distribution, metabolism, excretion, and real-world dosing implications backed by FDA label data and primary literature.
Farxiga Rebound Effects When Stopping: What the Evidence Actually Shows
Stopping Farxiga (dapagliflozin) can trigger fluid retention, blood sugar rebound, and worsening heart failure within days. This evidence-based guide covers the mechanism, timelines, clinical trial data, and how to stop safely.
Farxiga Sexual Function Impact: What Dapagliflozin Does (and Doesn't Do) to Libido, Erectile Function, and Genital Health
A guide to how dapagliflozin (Farxiga) affects sexual function in men and women with type 2 diabetes, heart failure, and CKD, including trial data, mechanistic explanations, and clinical management of genital mycotic infections.
Farxiga Sleep Architecture Impact: What Dapagliflozin Does to Your Sleep
A clinician-level review of how dapagliflozin (Farxiga) affects sleep architecture, nocturia, OSA-related outcomes, and cardiorespiratory physiology, with primary-literature citations.
Farxiga Storage, Stability & Shelf Life: Complete Clinical Guide
Evidence-based guide to dapagliflozin (Farxiga) storage conditions, shelf life, and temperature stability, including what the FDA label actually requires and what happens when tablets are exposed to heat, light, or moisture.
How to Safely Stop Farxiga (Dapagliflozin): A Clinical Discontinuation Protocol
Dapagliflozin (Farxiga) has no FDA-labeled taper, but stopping removes diabetes, heart failure or kidney protection. Withhold it for 3 days before surgery.